WallStSmart

AbbVie Inc (ABBV)vsAlign Technology Inc (ALGN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 1434% more annual revenue ($62.82B vs $4.10B). ALGN leads profitability with a 10.5% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.57. ALGN earns a higher WallStSmart Score of 68/100 (B-).

ABBV

Buy

63

out of 100

Grade: C+

Growth: 4.0Profit: 8.0Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

ALGN

Strong Buy

68

out of 100

Grade: B-

Growth: 6.0Profit: 6.5Value: 8.0Quality: 5.3
Piotroski: 3/9Altman Z: 2.59
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-20.5%)

Margin of Safety

-20.5%

Fair Value

$168.19

Current Price

$201.55

$33.36 premium

UndervaluedFair: $168.19Overvalued
ALGNUndervalued (+40.6%)

Margin of Safety

+40.6%

Fair Value

$332.34

Current Price

$168.78

$163.56 discount

UndervaluedFair: $332.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.3/10
Market CapQuality
$358.55B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Debt/EquityHealth
-21.0610/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.578/10

Growing faster than its price suggests

Free Cash FlowQuality
$4.89B8/10

Generating 4.9B in free cash flow

ALGN3 strengths · Avg: 8.0/10
PEG RatioValuation
0.898/10

Growing faster than its price suggests

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

EPS GrowthGrowth
23.9%8/10

Earnings expanding 23.9% YoY

Areas to Watch

ABBV4 concerns · Avg: 2.3/10
Profit MarginProfitability
5.8%3/10

5.8% margin — thin

P/E RatioValuation
98.9x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-45.8%2/10

Earnings declined 45.8%

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

ALGN2 concerns · Avg: 3.5/10
P/E RatioValuation
28.4x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.

Bull Case : ALGN

The strongest argument for ALGN centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.89 suggests the stock is reasonably priced for its growth.

Bear Case : ABBV

The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.

Bear Case : ALGN

The primary concerns for ALGN are P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

ALGN carries more volatility with a beta of 1.70 — expect wider price swings.

ABBV is growing revenue faster at 12.4% — sustainability is the question.

ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ALGN scores higher overall (68/100 vs 63/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Align Technology Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Align Technology is a manufacturer of 3D digital scanners and the Invisalign clear aligners used in orthodontics. It is headquartered in San Jose, California.

Want to dig deeper into these stocks?